FIELD: pharmaceuticals; medicine.
SUBSTANCE: invention relates to a method of enhancing the cytotoxic effect of panobinostat on tumor cells of the MCF-7, HeLa, PC-3 lines, characterized by the following: the tumor cells are pre-treated with an HSF1 inhibitor before treatment with panobinostat at a concentration of 2–400 nM, selected from 40 μM quercetin, 20 nM triptolide, 200 μM KNK437, 20 μM NZ28, 20 μM KRIBB11, or siRNA vector for HSF1 knockdown.
EFFECT: preventing the side effects of panobinostat using agents that inhibit the activation of HSF1 and the accumulation of HSPs in target cancer cells treated with panobinostat.
1 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC CANCER VACCINE BASED ON STRESS PROTEINS AS IMMUNOGENS | 2014 |
|
RU2694761C2 |
| INDUCING CELL DEATH BY INHIBITION OF ADAPTIVE HEAT SHOCK RESPONSE | 2009 |
|
RU2474612C2 |
| METHOD OF REDUCING THE NUMBER OF STEM CELLS OF HUMAN BREAST ADENOCARCINOMA | 2022 |
|
RU2798550C2 |
| USE OF THIOCHROMENO[2,3-C]QUINOLINE-12-ONE COMPOUND FOR TREATING NON-SMALL CELLS LUNG CANCER | 2016 |
|
RU2663929C2 |
| PEPTID, OBTAINED FROM HSP70, A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER, CONTAINING SUCH PEPTID, IMMUNE RESPONSE INDUCTOR AND METHOD FOR OBTAINING ANTIGEN-PRESENTING PATH | 2015 |
|
RU2684911C2 |
| MEANS OF ANTI-CLONOGENIC ACTIVITY IN RESPECT OF TUMOR HUMAN CELLS | 2016 |
|
RU2648820C2 |
| COMPOSITION INHIBITING TUMOR GROWTH AND SURVIVAL RATE | 2019 |
|
RU2707554C1 |
| METHOD OF INHIBITING RADIATION-INDUCED INCREASE IN HUMAN BREAST CANCER STEM CELLS | 2022 |
|
RU2800366C2 |
| METHOD FOR REDUCING CLONOGENIC ACTIVITY OF LACTEAL GLAND CANCER STEM CELLS | 2019 |
|
RU2700695C2 |
| STRAIN E coli BL21(DE3)/pET-hHSP70 - PRODUCENT OF PROTEIN OF HEAT SHOCK IN HUMANS HSP70 | 2006 |
|
RU2333956C1 |
